Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
HRTX · NASDAQ · Pharmaceutical Preparations
$0.2525−0.0116 (−4.39%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Heron Therapeutics, Inc. (HRTX) · oqro.io/stocks/HRTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Fund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 13, 2026
Rubric Capital Management LP disclosed an increased position in HRTX for Q4 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 14, 2025
Rubric Capital Management LP disclosed an increased position in HRTX for Q3 2025SourceInsider trade · Traded Aug 8, 2025 · Filed Aug 12, 2025
Director purchased ~$2.65M of HRTX shares in the open marketSourceInsider trade · Traded Aug 8, 2025 · Filed Aug 12, 2025
10% owner purchased ~$3.58M of HRTX shares in the open marketSourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
Orbimed Advisors LLC no longer reported HRTX for Q3 2024SourcePolitician trade (House) · Transaction Mar 31, 2021 · Disclosed Apr 5, 2021
Disclosed sale of HRTX — reported range $1,001 - $15,000Source